Back to Search
Start Over
Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial
- Authors :
- Bayani, J. Yao, C. Q. Quintayo, M. A. Haider, S. and Brookes, C. L. Yan, F. van de Velde, C. J. H. Hasenburg, A. and Kieback, D. G. Markopoulos, C. Dirix, L. Seynaeve, C. and Boutros, P. C. Rea, D. W. Bartlett, J. M. S.
- Publication Year :
- 2016
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.od......2127..00d174dd125fbd4c85c5e28bc29c2dfb